tirzepatide approval approved for weight loss Eli Lilly's Tirzepatide Weight-Loss Drug

Review Article OPEN ACCESS Dongjie Wu 1,# , Qingjuan Wu 1 , Yanxuan Wu 2 , Ziwei Guo 1 , Li Wang 1 , Yi Wang 1,3 , Qian Zeng 4 , Liang Shi 2 , Bin Shi 2 , Gongchang Yu 2,* and Wenliang Lv 1,* Author information Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD), the most common chronic liver disorder worldwide, results from multidimensional network dysregulation involving lipid metabolism imbalance, insulin resistance, oxidative stress, chronic inflammation, and gut-liver axis disruption

So, it's not being used clinically yet

Further reading: Dementia patients may also benefit from occupational therapy

This works well if you have straightforward health history and prefer not to schedule a live appointment

The main symptoms include nausea, vomiting, feeling full quickly, bloating, and stomach pain [4]